Latent tuberculosis infection
diseaseOn this page
Also known as inactive TBinactive tuberculosisLTBItuberculosis infection latent
Summary
Latent tuberculosis infection (MONDO:0040753) is a disease and 45 clinical trials. Top therapeutic interventions include isoniazid, rifapentine, and rifampin. A subtype of tuberculosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 45
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | latent tuberculosis infection |
| Mondo ID | MONDO:0040753 |
| MeSH | D055985 |
| SNOMED CT | 11999007 |
| UMLS | C1609538 |
| MedGen | 294255 |
| GARD | 0025831 |
| Is cancer (heuristic) | no |
Also known as: inactive TB · inactive tuberculosis · LTBI · tuberculosis infection latent
Disease family
This is a subtype of tuberculosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › primary bacterial infectious disease › tuberculosis › latent tuberculosis infection
Related subtypes (11): extrapulmonary tuberculosis, pulmonary tuberculosis, endocrine tuberculosis, tuberculoma, drug-resistant tuberculosis, active tuberculosis, tuberculous encephalopathy, primary tuberculous lymphadenitis, primary bone and joint tuberculosis, multifocal tuberculosis, primary tuberculosis of the digestive system
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 45.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 27 |
| PHASE3 | 8 |
| PHASE4 | 5 |
| PHASE2 | 2 |
| EARLY_PHASE1 | 2 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05680415 | PHASE4 | ACTIVE_NOT_RECRUITING | Clinical Trial of Mica |
| NCT06874725 | PHASE4 | ACTIVE_NOT_RECRUITING | Latent Tuberculosis in Type 2 Diabetes |
| NCT01223534 | PHASE4 | COMPLETED | QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study. |
| NCT01875952 | PHASE4 | UNKNOWN | Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL) |
| NCT05746611 | PHASE4 | COMPLETED | Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein |
| NCT00170209 | PHASE3 | COMPLETED | Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9) |
| NCT00931736 | PHASE3 | COMPLETED | Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectiveness |
| NCT01398618 | PHASE3 | UNKNOWN | Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI) |
| NCT01582711 | PHASE3 | COMPLETED | Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT |
| NCT01761201 | PHASE3 | TERMINATED | Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients. |
| NCT02208427 | PHASE3 | UNKNOWN | Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan |
| NCT04094012 | PHASE3 | COMPLETED | Risk of SDRs Under 3HP and 1HP Regimen for LTBI |
| NCT05899179 | PHASE3 | COMPLETED | Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above |
| NCT01136161 | PHASE2 | COMPLETED | Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection |
| NCT04272242 | PHASE2 | TERMINATED | Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals |
| NCT00546273 | PHASE1 | COMPLETED | Clinical Trial to Study 4 Different Doses of the Vaccine RUTI in Healthy Volunteers |
| NCT01549457 | EARLY_PHASE1 | UNKNOWN | TB mHealth Study - Use of Cell Phones to Improve Compliance in Patients on LTBI Treatment |
| NCT05027958 | EARLY_PHASE1 | COMPLETED | Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung |
| NCT06033807 | Not specified | RECRUITING | Active Screening of Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients |
| NCT06728930 | Not specified | ENROLLING_BY_INVITATION | Evaluation of a Novel Microbiological Diagnostic Test for Latent Mycobacterium Tuberculosis Infection |
| NCT07210970 | Not specified | NOT_YET_RECRUITING | Prevalence of Latent Tuberculosis Infection Among Hemodialysis Patients |
| NCT07608601 | Not specified | NOT_YET_RECRUITING | Latent Tuberculosis Infection Screening Using QuantiFERON at Pre-Employment Assessment in Hospital Workers CHu Nice |
| NCT00449345 | Not specified | UNKNOWN | Screening for Latent Tuberculosis in Healthcare Workers With Quantiferon-Gold Assay: A Cost-Effectiveness Analysis |
| NCT00463086 | Not specified | COMPLETED | Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons |
| NCT00541294 | Not specified | COMPLETED | Diagnosis of Tuberculosis Infection in HIV Co-infected Children |
| NCT00557765 | Not specified | COMPLETED | Use of a Gamma-IFN Assay in Contact Tracing for Tuberculosis in a Low-Incidence, High Immigration Area |
| NCT00558480 | Not specified | WITHDRAWN | Vitamin A Supplementation for Modulation of Mycobacterium Tuberculosis Immune Responses in Latent Tuberculosis |
| NCT00692809 | Not specified | UNKNOWN | Impact of HIV Infection on Latent Tuberculosis (TB) Among Patients With HIV-TB Co-infection |
| NCT00804713 | Not specified | COMPLETED | Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits |
| NCT00805272 | Not specified | COMPLETED | Medical and Economical Impact of IGRAs Diagnosis of Latent Tuberculosis in HIV-infected Patients |
| NCT00905970 | Not specified | UNKNOWN | Demonstration of the Dynamic Hypothesis of Latent Tuberculosis Infection |
| NCT01007396 | Not specified | COMPLETED | Diagnosis of Tuberculosis Infection in Health Care Workers Using Ex-vivo Interferon-gamma Assay |
| NCT01608685 | Not specified | COMPLETED | Interferon Gamma Release Assays (IGRA) Testing Versus Tuberculin Skin Test in Renal Transplant Recipients |
| NCT01622140 | Not specified | COMPLETED | Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis |
| NCT02225158 | Not specified | TERMINATED | Immune Responses to Mycobacterium Tuberculosis (Mtb) in People With Latent Tuberculosis Infection With or Without Concomitant Helminth Infection |
| NCT02641106 | Not specified | COMPLETED | VDOT for Monitoring Adherence to LTBI Treatment |
| NCT02810678 | Not specified | COMPLETED | Enhancing the Public Health Impact of Latent Tuberculosis (TB) Infection Diagnosis and Treatment |
| NCT03312647 | Not specified | UNKNOWN | Adverse Drug Reactions to Anti-TB Drugs in the Treatment of Latent Tuberculosis Infection |
| NCT03702049 | Not specified | COMPLETED | Nurse-Led Community Health Worker Adherence Model in 3HP Delivery Among Homeless Adults at Risk for TB Infection and HIV |
| NCT04048018 | Not specified | COMPLETED | Performance Evaluation of the VIDAS TB-IGRA Assay. |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ISONIAZID | 4 | 9 |
| RIFAPENTINE | 4 | 5 |
| RIFAMPIN | 4 | 2 |
| DOLUTEGRAVIR | 4 | 1 |
| RETINOL | 4 | 1 |
| CHEMBL1340583 | 0 | 5 |
Related Atlas pages
- Drugs: Isoniazid, Rifapentine, Rifampin, Dolutegravir, Retinol